Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Prediction of Thromboembolic Recurrences in Cancer Patients With Venous Thromboembolic Disease (TED)

Next Previous
Trial Profile

Prediction of Thromboembolic Recurrences in Cancer Patients With Venous Thromboembolic Disease (TED)

Status: Completed
Phase of Trial: Phase IV

Latest Information Update: 25 Jan 2024

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Tinzaparin sodium (Primary)
  • Indications Venous thromboembolism
  • Focus Therapeutic Use
  • Acronyms PREDICARE
  • Sponsors LEO Pharma

Most Recent Events

  • 12 Dec 2023 Results (n=1413) a meta-analysis from this and NCT02898051, NCT01164046 and NCT01130025 studies on individual patient level data to report the rate of rVTE and MB by 6 months according to site of cancer from prospective studies involving CAT patients on tinzaparin, presented at the 65th American Society of Hematology Annual Meeting and Exposition
  • 20 Apr 2021 Results published in the Thrombosis and Haemostasis
  • 31 May 2020 Primary endpoint has not been met. (Venous thromboembolism recurrence), as reported in an abstract presented at the 56th Annual Meeting of the American Society of Clinical Oncology

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top